Alterity Therapeutics (PRNAD) Depreciation & Amortization (CF) (2020)

Alterity Therapeutics (PRNAD) has reported Depreciation & Amortization (CF) for 14 consecutive years, with $1395.2 the latest figure, recorded in Q4 2025.

• In Q4 2025, Depreciation & Amortization (CF) fell 87.35% year-over-year to $1395.2; the TTM figure through Dec 2025 stood at $12422.2 (down 45.93% YoY), while the FY2025 annual figure was $18128.7, down 22.17% from the prior year.
• Depreciation & Amortization (CF) came in at $1395.2 for Q4 2025 at Alterity Therapeutics, down from $11027.0 in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $12924.9 in Q4 2022, with the low at $1395.2 in Q4 2025.
• Average Depreciation & Amortization (CF) over 5 years is $8421.1, with a median of $11027.0 recorded in 2024.
• Across the five-year window, Depreciation & Amortization (CF) soared 168.73% in 2022 and sank 87.35% in 2025, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $4809.6 in 2021, then jumped by 168.73% to $12924.9 in 2022, then slipped by 7.55% to $11948.9 in 2023, then dropped by 7.72% to $11027.0 in 2024, then tumbled by 87.35% to $1395.2 in 2025.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $1395.2, $11027.0, and $11948.9 for Q4 2025, Q4 2024, and Q4 2023 respectively.